Saturday, October 3, 2026

EVI Industries. Margin inflection or fake out?

EVI Industries says its ERP and service-platform build is largely complete, testing whether 10.8% revenue growth can finally outpace operating costs and lift margins.

EVI $248M

Kairos Research Oct 2 2 clicks

Oct 2 MRP $3.8B

EXCLUSIVE: Lennar’s Big New Customer Is Its Own Spinoff, Millrose

Hunterbrook 2 clicks

Oct 2 HUCK $145M

Single Stock Spotlight #16: Huckleberry.AI (HUCK)

Hidden Rock Capital's Newsletter 5 clicks

From X

@finphysnerd Oct 3 2 clicks

Myles on X

Adding long exposure (through $IWM and $RSP mainly) makes me feel sick, which backs up my belief that the timing is good to add long exposure.

@irbezek Oct 3 1 click

Ian Bezek on X

@coffeesnob @DELAESPRIELLAE Fun because this is 1. my local airport and 2. an $ASR property.

@calvinblissett Oct 3 1 click

Calvin Blissett on X

@UsefulSupplyCo @grok for $ARTNA respond with the correct figures about what I mentioned and is there any current analyst coverage? If so how many, who and what price target

@finphysnerd Oct 3 1 click

Myles on X

@whatsgoingoninm $HHH is a little different. The fee structure is weird and they have a weirder collection of assets, not just a bunch of publically listed stocks anyone can buy. Though no capital returns. Still not a great structure but not as egregious as PSH.

@majgeoinvesting Oct 3 5 clicks

Maj Soueidan on X

$FEIM (defense) was a great example of this. Not only was backlog growing, it was replacing sub 30% gross margin backlog with over 40% GM. You had all day to buy the stock between $8 & $15 in 2024. Now it’s pushing $100. $SIF (defense) might be approaching that type of set-up. https://t.co/wZh0Jqi3dz

@calvinblissett Oct 3 1 click

Calvin Blissett on X

@CompoundingEV There is no semi comprehensive tweet on $PAHC, there is no where for people to see a snapshot of it in such a pleasing manner unless they have value line. To me at least it’s nicer reading a quick pitch complied by a human than asking AI

@calvinblissett Oct 3 1 click

Calvin Blissett on X

$PAHC: 9x cash flow. 26% ROE Animals have to be healthy whether the economy is good or bad, and livestock producers have an economic incentive to spend money on products that reduce mortality, improve feed conversion, increase yield or prevent disease. 22% Adj EBITDA margin. JPM $55 PT. The company operates through the following business divisions: Animal Health division manufactures and sells animal health products such as antibacterial, anticoccidials, nutritional specialty products and vaccines used in the animal health industry to treat or to prevent bacterial diseases to improve the animal’s health. Mineral Nutrition division manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds. Performance Products division manufactures and markets various specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The most tangible new initiative is the planned closure of Chicago Heights, Illinois. Phibro acquired the facility as part of the Zoetis deal, reviewed its manufacturing network and decided it no longer made economic sense to keep the facility open. Production is expected to cease in summer 2027, affecting roughly 100 employees. Production will be shifted to other Phibro facilities and selected third-party manufacturers. Phibro Animal Health Corporation Management says the point is straightforward: align manufacturing capacity with future needs, improve efficiency and strengthen competitiveness. Phibro Animal Health Corporation The company expects approximately $10m of one-time cash costs and about $10m of capex, with eventual annual EBITDA benefit estimated around $15–20m, largely from FY2028 onward Regulatory optionality: Brazil virginiamycin One of the most interesting hidden catalysts is virginiamycin in Brazil. FY2027 guidance assumes only minimal sales because Phibro has not yet obtained the required therapeutic indications. FY2026 virginiamycin sales in Brazil were roughly $27m. Management explicitly said a favorable regulatory result could therefore provide modest upside to guidance.

@calvinblissett Oct 3 1 click

Calvin Blissett on X

$FSBW: Bought Pacific West Bank in August for 30m. Exp +7.5% EPS growth in 2027 due to this. PWBK has a 92% deposit mix NOT CDs. (attractive b/c lower cost). First Bancorp a bit cyclical due to home lending, consistent double digit ROE, conservative way to play eventual housing rebound. The problem was not that Pacific West had no franchise. It had a recognizable Portland commercial-banking niche, a relatively attractive deposit base, and specialized relationships with SMBs, nonprofits, professional-services businesses and digital partners. The problem was scale. Management acknowledged that Pacific West's size and market position made both organic and strategic growth difficult, while the cost and complexity of running a regulated community bank had risen materially after 2008 and 2020.

Rocket Lab (NASDAQ: RKLB) Stock Rating: Accumulate After Q2 FY12/26 Earnings

Rocket Lab reported Q2 revenue up 62% to $234.1 million and backlog up 137% to $2.36 billion, while operating losses and cash burn…

IRDM $5B

Cestrian Capital Research Oct 2

Research & Analysis | AAR Corp. (NYSE: AIR): MRO Holdings Reshapes the Margin Profile

AAR’s $1.8 billion acquisition of a 65% stake in MRO Holdings adds widebody aircraft maintenance and targets a 19% to 20% EBITDA margin by…

AIR $4B

Monte Independent Investment Research Oct 2 4 clicks

The Trade Desk (NASDAQ: TTD) Stock Rating: Do Nothing After Q2 FY12/26 Earnings

The Trade Desk's Q2 revenue grew 3% to $715 million as Q3 guidance called for a year-over-year decline; TTD has fallen over 90% from its…

TTD $5.8B

Cestrian Capital Research Oct 2 1 click

Belden Inc.: The Ruckus Debt Looks Scarier Than The Math

Belden targets net leverage of 2.9x by 2027 from 3.9x, using RUCKUS's 65%+ gross margins and free cash flow to reduce debt.

BDC $4.3B

Lee Bailey Oct 2

Crocs: Double-Digit Buyback Yield (Ticker: CROX)

Crocs has $2 billion of buyback authorization, more than a third of its market cap, as North American sales stabilize and HeyDude drags on…

CROX $5.6B

Emerging Moats Research Oct 2 4 clicks

$TPB: can Turning Point Brands be the third player in nicotine pouches? | Saberpoint Capital

Turning Point Brands' FRE and Alp nicotine pouches aim to become a third C-store brand behind ZYN and Velo as PMTA rules limit new entrants.

TPB $1.1B

Yet Another Value Podcast Oct 1 2 clicks

Mattel: M&A Buzz And A CEO Change Create Substantial Uncertainty

Mattel rose 19% on takeover speculation, but a potential $20-per-share bid, margin pressure and CEO transition leave its standalone…

MAT $4.8B

Seeking Profits Oct 1

How Ethos Sold Wall Street on AI While Powering an Analog Boiler Room

Ethos Technologies ($LIFE) sells AI-driven life insurance while relying heavily on multilevel marketing agencies using aggressive cold…

LIFE $2.2B

Hunterbrook Oct 1 1 click

Karman Holdings q2’26 Earnings Update

Karman Holdings reported 58% Q2 revenue growth, $1.3 billion backlog and margin expansion while replacing leadership and remediating…

KRMN $4.2B

Monte Independent Investment Research Oct 1

Innodata: The 45% Pullback Has Changed My View (Rating Upgrade)

Innodata's 45% pullback resets its valuation after two quarters of 50% revenue growth, though two customers still supply 71% of revenue and…

INOD $2.2B

Kurt Christensen Oct 1

LWAY · long

Lifeway Foods INC

Lifeway Foods holds 95% market share in kefir, is growing 20% to 35%, and trades at 12 times projected 2027 earnings as its capex cycle…

LWAY $320M

Value Investors Club Jun 3

Theravance Biopharma: Failed Phase 3 Trial, Strategic Review

Theravance Biopharma began a strategic review after a failed Phase 3 trial.

TBPH $884M

Clark Street Value Mar 5 2 clicks

The Green Dot Breakup: Grocery Money, Not Coffee Money

Green Dot’s breakup offers $8.11 cash plus 0.2215 BankCo shares, while GDOT’s $11.50 price implies a 0.55x tangible-book valuation for the…

GDOT $716M

Rod’s Ruminations Mar 5

Updates: TerraVest, Seaport Entertainment, XPEL (TVK.TO, SEG, XPEL)

Seaport Entertainment sold 250 Water St for $142 million and leased the loss-making Tin Building, while TerraVest’s Q1 cash EBIT margin…

SEG $286MTRRVF $1.6B

Hidden Gems Investing Mar 3

Single Stock Spotlight #3: Alpha Metallurgical Resources (AMR)

Alpha Metallurgical Resources has retired more than 30% of its shares since 2022; higher structural metallurgical-coal costs could support…

AMR $2.2B

Hidden Rock Capital's Newsletter Mar 3

Hydreight Technologies Inc. (NURS.V)

Hydreight Technologies (NURS.V) is a digital-health business with growing revenue, partners and customers, positioned as an acquisition…

HYDTF $131M

Byron Street Research Mar 2

Sleep Well Portfolio (Feb 2026) - Software AI risk Assessed

Sleep Well Portfolio cuts SPS Commerce after assessing AI risk across 12 software holdings, finding deterministic, rule-based data…

SPSC $2.9B

Sleep Well Investments Mar 2

Alta Fox XPEL Presentation

XPEL targets 26% EBIT margins by FY28 after its 2022-2025 investment cycle, with Alta Fox projecting roughly doubled EPS from FY25.

XPEL $1.2B

Research - Alta Fox Capital Mar 1

Coffee Money From the CaSaaStrophe: DCBO and YEXT Odd-Lot Tenders

Docebo and Yext odd-lot tenders prioritize holders under 100 shares; DCBO offers $20.40 per share, though Canadian deemed-dividend…

DCBO $623MYEXT $680M

Rod’s Ruminations Feb 26

2025 Bilbel Capital Annual Letter

Bilbel Capital’s 2025 letter details CareCloud’s $16.5M Medsphere acquisition, targeting $35–40M EBITDA in 2026, and recounts losses from…

CCLD $82M

Bilbel's Substack Feb 25 1 click

Publications we follow

Every publication on this site, hand-picked.

109 publications

YouTube 4

Blogs 12

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts

Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Saturday, October 3, 2026

Myles on X

Ian Bezek on X

Calvin Blissett on X

Myles on X

Maj Soueidan on X

Calvin Blissett on X

Calvin Blissett on X

Calvin Blissett on X

Investor Letters

Publications we follow

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 222

X accounts we follow

Investor letters we follow

Sectors